Expert Insights from PALOMA-3: Highlights from ASCO 2024

Opinion
Video

Wade T. Iams, MD, outlines insights gleaned from recently presented data from the PALOMA-3 trial in advanced EGFR-mutant non–small cell lung cancer.

Video content above is prompted by the following:

  • Briefly comment on key data from PALOMA and PALOMA-3 recently presented at ASCO 2024.
Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.

Enhanced Postoperative Recovery May Improve Outcomes in Elderly NSCLC

Roman Fabbricatore
January 28th 2025
Article

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Enhanced Dermatologic Care Reduced AEs from MARIPOSA Regimen in NSCLC

Enhanced Dermatologic Care Reduced AEs from MARIPOSA Regimen in NSCLC

Tim Cortese
January 22nd 2025
Article

Doxycycline/minocycline, clindamycin, chlorhexidine, and a ceramides-based noncomedogenic moisturizer reduced skin- and nail-related AEs in NSCLC.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Advancement of First-Line Treatments on EGFR-Mutated NSCLC

Advancement of First-Line Treatments on EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.